Clinical Trials

30 enrolled

Phase NA Not yet recruiting

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT07499128 2026-04-22

Continuous Temperature Monitoring (CTM) for Cytokine Release Syndrome (CRS), an Immune-Related Adverse Event

136 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Cytokine Release Syndrome, Lymphoma, Multiple Myeloma, Neoplasms, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03623373 2026-04-21

Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma

Phase 2 Completed

13 enrolled 13 charts

Lymphoma, Mantle-Cell

NCT02717624 2026-04-20

A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL

72 enrolled

Phase 1/2 Active not recruiting

Lymphoma, Mantle-Cell

NCT03932331 2026-04-20

Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies

105 enrolled 34 charts

Phase 1/2 Active not recruiting

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT04939272 2026-04-20

Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

8 enrolled

Lymphoma, Mantle-Cell

NCT05020678 2026-04-20

NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers

LymphoidOther hematologic neoplasmSarcoma

150 enrolled

Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell, Dendritic Cell Sarcoma, Interdigitating

NCT05724121 2026-04-20

Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax

Recruiting

135 enrolled

Arrhythmias, Cardiac, Atrial Fibrillation, Leukemia, Lymphocytic, Chronic, B-Cell, Death, Sudden, Cardiac, Hematologic Neoplasms, Lymphoma, Mantle-Cell

NCT06252675 2026-04-20

Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

30 enrolled

Lymphoma, Mantle-Cell

NCT06859008 2026-04-20

Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

37 enrolled

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT05294731 2026-04-17

Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader

146 enrolled

Phase 2 Not yet recruiting

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT07453095 2026-04-17

Study With Glofitamab in Patients With MCL and Inadequate Response or Relapse Following CAR T-cell Therapy

41 enrolled

Recurrence, Lymphoma, Mantle-Cell

NCT04189757 2026-04-16

Acalabrutinib for the Treatment of Ibrutinib-Intolerant Mantle Cell Lymphoma

9 enrolled

Lymphoma, Mantle-Cell

NCT06522386 2026-04-16

GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma

50 enrolled

Lymphoma, Mantle-Cell

NCT07003295 2026-04-16

Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy

20 enrolled

Lymphoma, Mantle-Cell

NCT04329728 2026-04-15

OPAL

144 enrolled

Leukemia, Lymphoma, Lymphoma, Follicular, Lymphoproliferative Disorders, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Biphenotypic, Acute, Leukemia, T-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT04491370 2026-04-15

Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma

20 enrolled

Burkitt Lymphoma, Hodgkin Disease, Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT05529069 2026-04-15

Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients

30 enrolled

Lymphoma, Non-Hodgkin, Hematologic Neoplasms, Lymphoma, Mantle-Cell

NCT05131022 2026-04-14

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

572 enrolled

Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT06544265 2026-04-14

SynKIR-310 for Relapsed/Refractory B-NHL

36 enrolled

LymphoidSarcoma

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Pyloric Stenosis, Hypertrophic, Dendritic Cell Sarcoma, Interdigitating

NCT01695941 2026-04-13

Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma

24 enrolled

Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT01804686 2026-04-13

CAN3001

Phase 3 Recruiting

700 enrolled

Bronchiolitis Obliterans Syndrome, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT02159755 2026-04-13

Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma

28 enrolled

Lymphoma, Mantle-Cell

NCT06564038 2026-04-13

Soundtrack-E

408 enrolled

Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT03478514 2026-04-09

Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma

39 enrolled

Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT04911478 2026-04-09

Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells

Active not recruiting

50 enrolled

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT01661881 2026-04-08

Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell Lymphoma

23 enrolled 8 charts

Lymphoma, Mantle-Cell

NCT04488354 2026-04-08

Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T

Phase 1 Completed

16 enrolled

Burkitt Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Hematologic Neoplasms, Lymphoma, Mantle-Cell

NCT05776134 2026-04-08

Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel

Available

Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07029737 2026-04-08

SOUND-MCL

55 enrolled

Lymphoma, Mantle-Cell

NCT05976763 2026-04-07

Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

Phase 3 Recruiting

421 enrolled

Lymphoma, Mantle-Cell

NCT06675123 2026-04-07

Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma

10 enrolled

Lymphoma, Mantle-Cell

NCT06208735 2026-04-03

CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies

24 enrolled

Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT04903197 2026-04-01

Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma

Phase 1 Terminated

18 enrolled

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT02051257 2026-03-31

Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma

51 enrolled

Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT06553872 2026-03-31

Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL

60 enrolled

Lymphoma, Mantle-Cell

NCT06533579 2026-03-30

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

32 enrolled

Burkitt Lymphoma, Leukemia, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Biphenotypic, Acute, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT02682641 2026-03-27

Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL

50 enrolled

Lymphoma, Mantle-Cell

NCT05753501 2026-03-27

Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies

135 enrolled

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Hematologic Neoplasms, Lymphoma, Mantle-Cell

NCT06192888 2026-03-27

A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma

39 enrolled

Lymphoma, Mantle-Cell

NCT06542250 2026-03-27

TITANium

174 enrolled

Phase 2 Not yet recruiting

Lymphoma, Follicular, Recurrence, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT07341191 2026-03-25

Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy

40 enrolled

Recurrence, Lymphoma, Mantle-Cell

NCT02446236 2026-03-24

Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma

27 enrolled 11 charts

Lymphoma, Mantle-Cell

NCT01479842 2026-03-23

Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma

48 enrolled

Phase 3 Active not recruiting

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT03267433 2026-03-23

Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission

689 enrolled

Lymphoma, Mantle-Cell

NCT04115631 2026-03-23

A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma

360 enrolled

Lymphoma, Mantle-Cell

NCT03282396 2026-03-20

Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma

20 enrolled

Lymphoma, Mantle-Cell

NCT04830137 2026-03-20

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

248 enrolled